<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092349</url>
  </required_header>
  <id_info>
    <org_study_id>HDZNRW-KA-007_KJG</org_study_id>
    <nct_id>NCT03092349</nct_id>
  </id_info>
  <brief_title>SonR Based Stimulation-VECtor OPTimisation in CRT Patients</brief_title>
  <acronym>VECTOPT</acronym>
  <official_title>Effect of SonR Based Stimulation-VECtor OPTimisation in Patients With Chronically Implanted Cardiac Resynchronization Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heart and Diabetes Center North-Rhine Westfalia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heart and Diabetes Center North-Rhine Westfalia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the present study is to investigate whether the optimisation of LVSV in
      addition to the optimisation of AV-D and VV-D when using the device-based sensor technology
      mentioned above results in an improved clinical outcome of CRT. Moreover, noninvasive
      measurements are intended to evaluate hemodynamic differences between the different
      stimulation configurations using the Finapres® method.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal Investigator has left study site
  </why_stopped>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NT-proBNP decrease (-15%)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2max (+ ≥0.7 ml/min/kg)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>NYHA class (improvement by ≥ 1 class)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>QOL (MLHF), score reduction (-15)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Cardiac Resynchronization Therapy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vector optimisation</intervention_name>
    <description>Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a CRT-D system providing the possibility of SonR-based optimisation of AV-D
        and VV-D
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Indication for CRT-D implantation according to guidelines at the time of implantation

          -  Implanted CRT-D system with SonR sensor technology

          -  Sinus rhythm

          -  NYHA class II-IV

          -  Age ≥ 18 years

          -  Written informed consent to participate in the study

        Exclusion Criteria:

          -  Patients having received a CRT system without SonR sensor technology

          -  Patients with an insufficient SonR signal

          -  Confirmed pregnancy

          -  Age &lt; 18 years

          -  Life expectancy &lt; 1 year

          -  Atrial fibrillation / atrial flutter at the time of enrollment

          -  Unability to give informed consent

          -  Participation in another clinical study with active therapeutic arm

          -  Regular follow-up at the study site from enrolment to 12 months follow up not
             guaranteed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus-Jürgen Gutleben, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic for Cardiology, Heart and Diabetes Center North Rhine-Westphalia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz- und Diabeteszentrum NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

